Researchers in the biopharma and medical device industries face an increasingly complex set of questions. Whether the questions relate to clinical effectiveness of therapies, the pharmacoeconomics of treatment, or disease cohort characteristics, researchers have historically had to resort to relying on claims data, that by definition, barely scratches the surface.

There is a growing trend among innovative biopharmaceutical research groups and analytics firms who are forging relationships with a small handful of technologically advanced healthcare systems, that through an electronic medical record (EMR) infrastructure can provide unparalleled access to troves of longitudinal, de-identified, high resolution clinical and lab data.

Consistent with this trend, Geisinger Health System - an innovative Mid-Atlantic based fully-integrated health system that includes a 700+ multi-specialty physician group practice, 3 hospitals, 40 ambulatory clinics, a health plan, three dedicated research centers, and an active clinical trials group connected seamlessly via an extensive, cross-continuum EMR platform - experienced a significant spike in requests from pharmaceutical companies, health analytics firms, and claims data vendors alike. In response, Ron Paulus, MD, and I, both with track records of founding and growing successful IT services companies, spearheaded the launch of MedMining, Geisinger's information services business that puts at our customer's fingertips the 11+ years of de-identified clinical, lab, and economic data resident in Geisinger's sophisticated electronic medical record system.

MedMining offers high-end, HIPAA-compliant, ad-hoc custom data extracts to the biopharma and device industries. Of particular note, with this clinical data platform advantage, you no longer need to rely solely on claims data which suffers from lack of both timeliness and depth despite its "industry norm" status. In short, our EMR based clinical data and associated economic information is deep, current and tied to ongoing, longitudinal clinician-patient relationships. As CEO of MedMining, I'm committed to providing the biopharma and device industries with a new opportunity for research that takes advantage of uniquely detailed, medical record-based data capable of providing insights into therapies, diseases, and outcomes that, until now, have been unimaginable.

In addition to the inherent strength of our data, I'm confident you'll find that the quality and timeliness of our work reflect our obsession with customer service. We recognize that no two research questions will ever be the same. We treat each research question as a uniquely special endeavor, one that will receive the full attention of one of our dedicated teams. We look forward to helping you satisfy your mission critical clinical and related economic data needs. We are not just a data partner - we're a partner.

Please call us - we would appreciate the opportunity to add your organization to our impressive list of world-class pharmaceutical and health analytics customers.


James J. Peters
Chief Executive Officer, MedMining